GiACTA was a randomized, double-blind, placebo-controlled study that investigated the safety and efficacy of tocilizumab, an IL-6 receptor antagonist, in patients with giant cell arteritis. touchIMMUNOLOGY were delighted to speak with Dr. Naomi J Patel (Massachusetts General Hospital, Boston, MA, USA) to discuss the aims, design and findings from her post-hoc analysis of the GiACTA trial, that looked at the impact of glucocorticoids and tocilizumab on changes in HbA1C over time in those who completed the GiACTA trial.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘The Effects of Daily Prednisone and Tocilizumab on Hemoglobin A1c During the Treatment of Giant Cell Arteritis.’ (Abstract number: 0461) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- Could you give us a brief overview of the GiACTA trial and its findings? (0:09)
- What were the aims and design of this post-hoc analysis? (0:57)
- What was the impact of tocilizumab on HbA1C? (1:34)
- What was the reason for the observed association between tocilizumab and HbA1C reduction, and what further study is planned? (2:23)
- What are the key take-home messages of this study? (3:12)
Disclosures: Naomi J Patel has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
